Pepsin and Reflux Laboratory
To contact Dr. Johnson, please email njohnston@mcw.edu.
Learn More about Dr. Johnston
Current and Future Translational Research: Oral Formulation
Human Subject Research
This research investigates the effects of oral Fosamprenavir for treatment of LPR in Humans.
- Efficiency of Fosamprenavir Conversion by Established Human Laryngeal Epithelial Cell Cultures, in the Presence of Saliva and Sera, Measured by High-Performance Liquid Chromatography
- Proof of Concept, to Assess the Efficacy of Oral Fosamprenavir for Treatment of Laryngopharyngeal Reflux
Estimated Start Winter 2023
In Vitro Research
This research focuses on how amprenavir protects against Pepsin Mediated Laryngeal E-cadherin Cleavage and Matrix Metalloprotease Induction in vitro.
- Topical Alginate Protection against Pepsin-Mediated Esophageal Damage: E-Cadherin Proteolysis and Matrix Metalloproteinase Induction.
- The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.
In Vivo Research
- Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model
Current and Future Translational Research: Inhaled Formulation
Human Subject Research
Estimated Start Spring 2024
In Vivo
This research explores the toxicology and outcomes relating to Fosamprenavir for treatment of LPR in animal models.
- Toxicology of Inhaled Fosamprenavir as a Dry Powder for Laryngopharyngeal Reflux: Toxicology and Fluid Dynamics Modeling
- Toxicity of inhaled Fosamprenavir, a dose finding animal model
o Currently working with KreaMedica, Quebec Canada, on this study
In Vitro
This research investigates the ideal particle size and deposition rate of Fosamprenavir particles for inhalation targeting the larynx via Dry Powder Inhaler
- Computational Fluid Dynamic analysis of Inhaled Fosamprenavir
Research Timeline for Oral Suspension for LPR, Oral Suspension for GERD and Dry Powder Inhaler for LPR
European Union of Phonetricians Congress Presentation 2023
Taiwan Voice Society Annual Meeting in conjunction with International Voice Symposium of TCVGH September 2022
Learn more about Dr. Johnston and her team's research accomplishments.
Current Laboratory and Study Team Members
Nikki Johnston, PhD
Professor, Otolaryngology & Communication Sciences and Microbiology & Immunology
Jonathan Bock, MD
Professor
Joel H. Blumin, MD
Chief, Professor
Mark A. Vukovich, MSN, APNP
APP Outpatient
Tina Samuels, MS
Program Manager, Airway, Digestive, & Voice Research
Ally Lesnick
Research Coordinator
Simon Blaine-Sauer
Medical Student
Pelin Ergun, PhD
Postdoctoral Researcher
Recent Publications
-
17β-estradiol Attenuates the Middle Ear Inflammatory Response to Nontypeable Haemophilus influenzae.
(Khampang P, Samuels TL, Blaine-Sauer S, Lucas J, Yan K, Johnston N, Kerschner JE.) Laryngoscope. 2024 Aug;134(8):3815-3819 PMID: 38401061 SCOPUS ID: 2-s2.0-85186458928 02/24/2024
-
The Dubai Definition and Diagnostic Criteria of Laryngopharyngeal Reflux: The IFOS Consensus.
(Lechien JR, Vaezi MF, Chan WW, Allen JE, Karkos PD, Saussez S, Altman KW, Amin MR, Ayad T, Barillari MR, Belafsky PC, Blumin JH, Johnston N, Bobin F, Broadhurst M, Ceccon FP, Calvo-Henriquez C, Eun YG, Chiesa-Estomba CM, Crevier-Buchman L, Clarke JO, Dapri G, Eckley CA, Finck C, Fisichella PM, Hamdan AL, Hans S, Huet K, Imamura R, Jobe BA, Hoppo T, Maron LP, Muls V, O'Rourke AK, Perazzo PS, Postma G, Prasad VMN, Remacle M, Sant'Anna GD, Sataloff RT, Savarino EV, Schindler A, Siupsinskiene N, Tseng PH, Zalvan CH, Zelenik K, Fraysse B, Bock JM, Akst LM, Carroll TL.) Laryngoscope. 2024 Apr;134(4):1614-1624 PMID: 37929860 SCOPUS ID: 2-s2.0-85168811976 11/06/2023
-
Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling.
(Lesnick A, Samuels TL, Seabloom D, Wuertz B, Ojha A, Seelig D, Ondrey F, Wiedmann TS, Hogan C, Torii E, Ouyang H, Yan K, Garcia GJM, Bock JM, Johnston N.) Laryngoscope Investig Otolaryngol. 2024 Feb;9(1):e1219 PMID: 38362183 PMCID: PMC10866582 02/16/2024
-
Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling
(Lesnick A, Samuels TL, Seabloom D, Wuertz B, Ojha A, Seelig D, Ondrey F, Wiedmann TS, Hogan C, Torii E, Ouyang H, Yan K, Garcia GJM, Bock JM, Johnston N.) Laryngoscope Investigative Otolaryngology. February 2024;9(1) SCOPUS ID: 2-s2.0-85183005384 02/01/2024
-
Establishment of novel immortalized middle ear cell lines as models for otitis media.
(Blaine-Sauer S, Samuels TL, Khampang P, Yan K, McCormick ME, Chun RH, Harvey SA, Friedland DR, Johnston N, Kerschner JE.) Laryngoscope Investig Otolaryngol. 2023 Oct;8(5):1428-1435 PMID: 37899851 PMCID: PMC10601576 10/30/2023